Weekly Investment Analysts’ Ratings Updates for Dicerna Pharmaceuticals (DRNA)

A number of research firms have changed their ratings and price targets for Dicerna Pharmaceuticals (NASDAQ: DRNA):

  • 2/9/2018 – Dicerna Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “
  • 2/5/2018 – Dicerna Pharmaceuticals is now covered by analysts at SunTrust Banks, Inc.. They set a “buy” rating and a $13.00 price target on the stock.
  • 2/2/2018 – Dicerna Pharmaceuticals was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 2/1/2018 – Dicerna Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “
  • 1/31/2018 – Dicerna Pharmaceuticals was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 1/25/2018 – Dicerna Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “
  • 1/25/2018 – Dicerna Pharmaceuticals was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 1/16/2018 – Dicerna Pharmaceuticals is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $14.00 price target on the stock.
  • 1/16/2018 – Dicerna Pharmaceuticals had its “neutral” rating reaffirmed by analysts at Chardan Capital.
  • 1/9/2018 – Dicerna Pharmaceuticals was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 12/31/2017 – Dicerna Pharmaceuticals was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.

Dicerna Pharmaceuticals Inc (DRNA) traded up $0.16 during trading hours on Thursday, reaching $9.60. The company’s stock had a trading volume of 239,500 shares, compared to its average volume of 375,958. Dicerna Pharmaceuticals Inc has a 1 year low of $2.52 and a 1 year high of $11.19. The firm has a market capitalization of $487.49, a PE ratio of -2.80 and a beta of 2.75.

In other Dicerna Pharmaceuticals news, Director Bain Capital Life Sciences Inv bought 285,000 shares of the firm’s stock in a transaction on Monday, December 18th. The stock was purchased at an average cost of $7.00 per share, with a total value of $1,995,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 29.41% of the stock is currently owned by insiders.

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Receive News & Ratings for Dicerna Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply